Nucor earnings beat by $0.08, revenue fell short of estimates
On Wednesday, analysts at Cantor Fitzgerald maintained their Neutral stance on Acadia Healthcare (NASDAQ:ACHC) shares, reiterating a $40.00 price target. The assessment was based on the observation that inpatient psychiatric data remain the strongest compared to peers and have shown stability in the second quarter of 2025 compared to the first quarter. According to InvestingPro data, the company’s revenue grew by 5.5% over the last twelve months, with analyst targets ranging from $28 to $72. The analyst noted that facilities previously mentioned in New York Times (NYSE:NYT) articles are on an upward trend, aligning with the overall company’s performance.
Acadia Healthcare, a provider of behavioral healthcare services, has been under scrutiny following reports in the New York Times. However, the analyst’s evaluation indicates that the mentioned facilities have shown improvements and are consistent with the company’s general trend. InvestingPro analysis shows the company maintains a "GOOD" overall financial health score, with particularly strong marks in relative value and profitability metrics. This observation suggests that the concerns raised have not significantly impacted the operational stability of the broader organization.
The analyst’s commentary underscores the performance of Acadia Healthcare’s inpatient psychiatric segment, which is a critical component of the company’s service offerings. The stability of this segment is essential for the company’s financial health, as it directly relates to the core business operations. With a gross profit margin of ~42% and current ratio of 1.35, the company demonstrates operational efficiency despite carrying a significant debt burden.Get access to more detailed insights and 12+ additional ProTips for ACHC through InvestingPro, including comprehensive analysis of the company’s debt structure and profitability metrics.
The reiterated price target of $40.00 reflects the analyst’s assessment of the company’s value based on the current data. While the Neutral rating indicates that the analysts do not see significant catalysts that could drive the share price substantially higher in the near term, it also suggests that they do not expect the company to underperform.
Investors and stakeholders in Acadia Healthcare will continue to monitor the company’s performance, particularly in light of the previous media attention, to gauge its progress and the effectiveness of its improvement measures. The company’s ability to maintain stability in its inpatient psychiatric services is likely to remain a key factor in its overall performance going forward.
In other recent news, Acadia Healthcare reported its first-quarter 2025 earnings, which met analyst expectations with a revenue of $770.5 million, slightly below the forecasted $777.25 million, but the company exceeded earnings per share (EPS) expectations with $0.40 against the anticipated $0.39. Despite the revenue miss, Acadia Healthcare maintained its full-year 2025 guidance, projecting revenues between $3.3 billion and $3.4 billion. Raymond (NSE:RYMD) James reaffirmed a strong buy rating with a $40.00 price target, while Cantor Fitzgerald and Mizuho (NYSE:MFG) Securities maintained a Neutral rating, with Mizuho adjusting its price target from $37 to $32.
KeyBanc Capital Markets also revised its outlook, lowering the price target from $65.00 to $55.00 but keeping an Overweight rating, indicating a positive long-term outlook. The company continues to expand its facilities, adding 378 new beds in the first quarter, and plans to add 600-800 beds annually from 2026 to 2028. Acadia Healthcare is currently navigating challenges related to patient volumes and legal investigations, but analysts like those from KeyBanc anticipate a recovery in patient volumes and cash flows over time.
The company remains focused on growth strategies such as facility expansion, mergers, and acquisitions, despite facing risks like increased labor costs and competition. Analysts from Mizuho and KeyBanc note that while Acadia Healthcare is on a path to recovery, it may take several years to achieve full normalization. The demand for behavioral health services remains robust, and Acadia Healthcare plans to capitalize on this demand as it continues to expand its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.